High-Throughput Volumetric Photoacoustic Imaging of Living Vascularized Organoids

活体血管类器官的高通量体积光声成像

基本信息

批准号：
10078867
负责人：
Junjie Yao
金额：
$ 49.46万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-01 至 2022-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10078867
关键词：
3-Dimensional Address Anatomy Angiogenesis Inhibitors Animal Model Biochemical Biomimetics Bioreactors Blood Vessels Capital Cardiovascular Diseases Cell Culture Techniques Cells Clinical Clinical Trials Detection Development Devices Diabetes Mellitus Diffusion Dimensions Disease Disease model Drug Interactions Drug Monitoring Drug Screening Drug toxicity Endothelial Cells Equilibrium Expenditure Functional Imaging Genetic Engineering Geometry Goals Histologic Human Image Investments Label Light Location Longitudinal Studies Malignant Epithelial Cell Malignant Neoplasms Malignant neoplasm of liver Mediating Metabolism Microfluidics Microscopy Modeling Molecular Monitor Neurodegenerative Disorders Neurology Nutrient Oncology Optics Organ Organoids Pathologic Pathology Patients Penetration Pharmaceutical Preparations Pharmacotherapy Physiological Physiology Preclinical Drug Development Primary carcinoma of the liver cells Process Property Reaction Resolution Structure System Technology Testing Therapeutic Three-Dimensional Imaging Time Tissue Engineering Tissue Model Tissues Ultrasonics United States Food and Drug Administration Vascularization anatomic imaging angiogenesis base bioprinting cancer imaging combat cost density drug candidate drug development drug efficacy drug testing experience high-throughput drug screening human disease human tissue imaging capabilities imaging modality improved in vivo microfluidic technology millimeter miniaturize molecular imaging novel novel therapeutics optical imaging optoacoustic tomography organ on a chip oxygen transport personalized medicine photoacoustic imaging response screening self assembly success tool transcription factor

项目摘要

Abstract Over the last decade, there has been a 62% rise in the number of therapeutic compounds under development for cancers, diabetes, neurodegenerative diseases, and cardiovascular diseases, and the total expenditure has nearly doubled. Despite the significant investment, the average number of new drugs approved by the Food and Drug Administration (FDA) has declined since the 1990s, mainly due to the low success rate of human clinical trials and the insufficient efficacy and/or excessive adverse (toxic) reactions associated with the candidate drugs. Planar cell cultures and animal models used in drug testing often fail to accurately reflect human physiology and pathology. Three-dimensional (3D) human cell-based organ-on-a-chip models, combined with advanced vascularization and microfluidics technologies, have been increasingly used to improve drug testing, by recapitulating important physiological parameters of their in vivo human counterparts. However, the characterization of 3D vascularized organoid cultures is challenging with pure optical imaging methods that reach only small depths (~1 mm) and/or lacks functional imaging capability. The organoids can reach 2–3 mm in all dimensions, and the response to the drug treatment by cells at different locations may significantly vary due to non-uniform tissue properties, limited molecular diffusion, and heterogeneous vascular arborization. To address these issues, we propose to develop a novel integrated imaging-bioreactor platform that combines a miniaturized photoacoustic tomography (mini-PAT) system (Aim 1) and a human vascularized organ-on-a-chip bioreactor (Aim 2). Mini-PAT can be directly integrated onto the bioreactor and provide critical anatomical and functional information about the 3D organoid’s development, vasculature function and metabolism. As proof of concept, we will apply the integrated platform for on-chip, longitudinal, and volumetric imaging of the progression of hepatocellular carcinoma (HCC) organoids, their multiscale vascularization, and their response to anti- angiogenic drugs (Aim 3). Most importantly, both the mini-PAT and bioreactor are highly compact and low-cost (~$200 per unit), so they can be readily multiplexed for monitoring a large array of organoids in parallel. The highly heterogeneous drug-organoid interactions can thus be simultaneously studied in a statistically meaningful manner. Ultimately, this proposal will provide a platform technology for a variety of applications that require high-throughput pathological testing on human tissue models. More excitingly, it would pave the way for personalized medicine screening using an array of patient-derived disease models.

抽象的过去十年，正在开发的治疗化合物数量增加了 62% 癌症、糖尿病、神经退行性疾病和心血管疾病的总支出尽管投资巨大，但食品和药物管理局批准的新药平均数量却增加了近一倍。药物管理局（FDA）自20世纪90年代以来一直在衰落，主要是由于人体临床成功率低试验以及与候选药物相关的疗效不足和/或过度不良（毒性）反应。药物测试中使用的平面细胞培养物和动物模型往往无法准确反映人体生理学和三维（3D）人体细胞器官芯片模型，结合先进的技术。血管化和微流体技术已越来越多地用于改进药物测试，概括了体内人体分子的重要生理参数。使用纯光学成像方法来表征 3D 血管化类器官培养物具有挑战性，这些方法可达到类器官的深度很小（~1 毫米）和/或缺乏功能成像能力。尺寸，并且不同位置的细胞对药物治疗的反应可能因以下原因而显着不同：不均匀的组织特性、有限的分子扩散和异质的血管树枝化。这些问题，我们建议开发一种新颖的集成成像生物反应器平台，该平台结合了小型化光声断层扫描 (mini-PAT) 系统（目标 1）和人体血管化器官芯片生物反应器（目标 2）Mini-PAT 可以直接集成到生物反应器上并提供关键的解剖学和功能。有关 3D 类器官发育、脉管系统功能和新陈代谢的信息作为概念证明，我们将应用集成平台进行片上、纵向和体积成像肝细胞癌 (HCC) 类器官、其多尺度血管化及其对抗肿瘤药物的反应血管生成药物（目标 3）最重要的是，微型 PAT 和生物反应器都非常紧凑且成本低廉。（每单位约 200 美元），因此它们可以很容易地进行多路复用，以并行监测大量的类器官。因此，可以以具有技术意义的方式同时研究高度异质的药物-类器官相互作用最终，该提案将为需要的各种应用程序提供平台技术。更令人兴奋的是，这将为人体组织模型的高通量病理测试铺平道路。使用一系列源自患者的疾病模型进行个性化医学筛查。